Cargando…
Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy
BACKGROUND: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs that require therapy adjustment beyond 12 months of treatment are ra...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293334/ https://www.ncbi.nlm.nih.gov/pubmed/37131100 http://dx.doi.org/10.1007/s10620-023-07950-0 |
_version_ | 1785062979170992128 |
---|---|
author | Jansen, Fenna M. Smits, Lisa J. T. Thomas, Pepijn W. A. de Jong, Dirk J. Kreijne, Joany E. van Dop, Willemijn A. den Broeder, Nathan Hoentjen, Frank |
author_facet | Jansen, Fenna M. Smits, Lisa J. T. Thomas, Pepijn W. A. de Jong, Dirk J. Kreijne, Joany E. van Dop, Willemijn A. den Broeder, Nathan Hoentjen, Frank |
author_sort | Jansen, Fenna M. |
collection | PubMed |
description | BACKGROUND: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs that require therapy adjustment beyond 12 months of treatment are rare. AIM AND METHODS: This single-center prospective cohort study evaluated the safety of a reduced 6-monthly monitoring strategy in steroid-free patients with quiescent IBD on stable dose of azathioprine, mercaptopurine, or thioguanine monotherapy. The primary outcome was thiopurine-related AEs requiring therapy adjustments during a follow-up period of 24 months. Secondary outcomes included all AEs including laboratory toxicity, disease flares until 12 months, and the net monetary benefit from this strategy concerning IBD-related health care use. RESULTS: We enrolled 85 patients with IBD (median age 42 years, 61% Crohn’s disease, 62% female), with a median disease duration of 12.5 years and median thiopurine treatment duration of 6.7 years. During follow-up, 3 patients (4%) ceased thiopurines due to AEs: recurrent infections, non-melanoma skin cancer, and gastrointestinal complaints (nausea, vomiting). At 12 months, 25 laboratory toxicities were observed (including 13% myelotoxicity, 17% hepatotoxicity); none required therapy adjustments and all were transient. A reduced monitoring strategy had a net benefit of €136 per patient. CONCLUSION: Three patients (4%) ceased thiopurine therapy due to thiopurine-related AEs, while no laboratory toxicity required therapy adjustments. Monitoring frequency of every 6 months seems feasible in patients with stable IBD on long-term (median duration > 6 years) maintenance thiopurine therapy and may contribute to reduced patient-burden and health care costs. |
format | Online Article Text |
id | pubmed-10293334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-102933342023-06-28 Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy Jansen, Fenna M. Smits, Lisa J. T. Thomas, Pepijn W. A. de Jong, Dirk J. Kreijne, Joany E. van Dop, Willemijn A. den Broeder, Nathan Hoentjen, Frank Dig Dis Sci Original Article BACKGROUND: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs that require therapy adjustment beyond 12 months of treatment are rare. AIM AND METHODS: This single-center prospective cohort study evaluated the safety of a reduced 6-monthly monitoring strategy in steroid-free patients with quiescent IBD on stable dose of azathioprine, mercaptopurine, or thioguanine monotherapy. The primary outcome was thiopurine-related AEs requiring therapy adjustments during a follow-up period of 24 months. Secondary outcomes included all AEs including laboratory toxicity, disease flares until 12 months, and the net monetary benefit from this strategy concerning IBD-related health care use. RESULTS: We enrolled 85 patients with IBD (median age 42 years, 61% Crohn’s disease, 62% female), with a median disease duration of 12.5 years and median thiopurine treatment duration of 6.7 years. During follow-up, 3 patients (4%) ceased thiopurines due to AEs: recurrent infections, non-melanoma skin cancer, and gastrointestinal complaints (nausea, vomiting). At 12 months, 25 laboratory toxicities were observed (including 13% myelotoxicity, 17% hepatotoxicity); none required therapy adjustments and all were transient. A reduced monitoring strategy had a net benefit of €136 per patient. CONCLUSION: Three patients (4%) ceased thiopurine therapy due to thiopurine-related AEs, while no laboratory toxicity required therapy adjustments. Monitoring frequency of every 6 months seems feasible in patients with stable IBD on long-term (median duration > 6 years) maintenance thiopurine therapy and may contribute to reduced patient-burden and health care costs. Springer US 2023-05-02 2023 /pmc/articles/PMC10293334/ /pubmed/37131100 http://dx.doi.org/10.1007/s10620-023-07950-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Article Jansen, Fenna M. Smits, Lisa J. T. Thomas, Pepijn W. A. de Jong, Dirk J. Kreijne, Joany E. van Dop, Willemijn A. den Broeder, Nathan Hoentjen, Frank Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy |
title | Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy |
title_full | Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy |
title_fullStr | Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy |
title_full_unstemmed | Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy |
title_short | Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy |
title_sort | feasibility of reduced clinical monitoring in patients with inflammatory bowel disease treated with thiopurine therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293334/ https://www.ncbi.nlm.nih.gov/pubmed/37131100 http://dx.doi.org/10.1007/s10620-023-07950-0 |
work_keys_str_mv | AT jansenfennam feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT smitslisajt feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT thomaspepijnwa feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT dejongdirkj feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT kreijnejoanye feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT vandopwillemijna feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT denbroedernathan feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy AT hoentjenfrank feasibilityofreducedclinicalmonitoringinpatientswithinflammatoryboweldiseasetreatedwiththiopurinetherapy |